Auto-injectors Market Segmentation:
Disease Indication Segment Analysis
The anaphylaxis segment in the auto-injectors market is estimated to gain a robust revenue share of 35% by the end of 2035. Globally, food allergies are becoming more common owing to various causes, including obesity, vitamin D deficiency, exposure to ambient chemicals, and others. This is pushing both public and private medical authorities to promote awareness about the available emergency relief options, including auto-injectors for these patients, creating a surge in this field. For instance, in June 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) released new guidelines suggesting carrying a minimum of two adrenaline auto-injectors as a part of the recent safety recommendations to combat the event of anaphylaxis, influencing more people to invest in this field.
Product Type Segment Analysis
Auto-injectors market from the disposable segment is set to garner a notable share. Disposable sub-types for prefilled syringes are simple to use and are meant for patients to administer fixed-dose injections subcutaneously. This essentiality solidifies this segment’s leadership over other types. As per an NLM article from September 2021, 62% of combination pharmaceutical products administrated through self-injectable devices were disposable. Furthermore, this segment is poised to grow with the increasing adoption of innovative technologies as they offer better patient compliance and adherence to antidotes, disease-modifying medicines, and monoclonal antibodies (2021 NLM article).
Our in-depth analysis of the global auto-injectors market includes the following segments:
|
Product Type |
|
|
Disease Indication |
|
|
End use |
|
|
Technology |
|
|
Route of Administration |
|
